4.7 Review

Genetic associations with brain microbleeds Systematic review and meta-analyses

Journal

NEUROLOGY
Volume 77, Issue 2, Pages 158-167

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318224afa3

Keywords

-

Funding

  1. Binks Trust, UK
  2. MRC UK
  3. FWO Flanders
  4. Scottish Funding Council
  5. Centre for Clinical Brain Sciences
  6. Wellcome Trust
  7. Binks Trust
  8. MRC
  9. Shire plc
  10. Boehringer Ingelheim
  11. Servier
  12. Schering-Plough Corp.
  13. Sygnis Pharma AG
  14. CoAxia, Inc.
  15. Medtronic, Inc.
  16. Novo Nordisk
  17. Bristol-Myers Squibb
  18. Pfizer Inc
  19. AstraZeneca
  20. ThromboGenics NV
  21. Eli Lilly and Company
  22. sanofi-aventis
  23. Daii-chi Sankyo
  24. Asubio Pharmaceuticals, Inc.
  25. Vlaams Instituut voor Biotechnologie (VIB)
  26. UK Stroke Association
  27. Chief Scientist Office of the Scottish Government Health Department
  28. Chest Heart & Stroke Scotland
  29. Chief Scientist Office of the Scottish Executive Health Department
  30. Stroke Association
  31. MRC [G1002605, G108/613] Funding Source: UKRI
  32. Medical Research Council [O12345678, G0700704B, G108/613] Funding Source: researchfish

Ask authors/readers for more resources

Objective: We performed a systematic review and meta-analyses to assess the evidence for genetic associations with brain microbleeds (BMBs). Methods: We sought all published studies of the association between any genetic polymorphism and BMBs studied in a total of >100 people. We critically appraised studies, and calculated pooled odds ratios (ORs) using the generic inverse variance fixed effects method. We used I-2 and chi(2) statistics to assess heterogeneity, and fail-safe N estimates to assess the robustness of our results. Results: Only the APOE epsilon 2/3/4 polymorphism had been studied in >100 people (10 studies, 7,351 participants). Compared with people with the epsilon 3/epsilon 3 genotype, carriers of the epsilon 4 allele (epsilon 4+) were statistically significantly more likely to have BMBs in any location (epsilon 4 + vs epsilon 3/epsilon 3: pooled OR 1.22, 95% confidence interval [CI] 1.05-1.41, p = 0.01). For strictly lobar BMBs, this association appeared slightly stronger (epsilon 4 + vs epsilon 3/epsilon 3: pooled OR 1.35, 95% CI 1.10-1.66, p = 0.005). The association of epsilon 4+ genotypes with strictly lobar BMBs was reasonably robust to potential publication and reporting biases. Conclusions: Given the known associations of APOE alleles with lobar intracerebral hemorrhage and cerebral amyloid angiopathy, these findings support the concept that strictly lobar BMBs may be an imaging biomarker of cerebral amyloid angiopathy. Neurology(R) 2011;77:158-167

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available